Phase 1 Recurrent Glioblastoma, IDH-Wildtype Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394